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a short questionnaire about socio-demographic data, adherence (Morisky Medica-
tion Adherence Scale) and knowledge (Michigan Diabetes Knowledge Test) while
medical records were reviewed for diabetes-related data. RESULTS: The mean age
was 58.16 years (SD9.16) with around 50% males. The mean MMAS score of the
patients was 6.11 (SD 1.66) and the total mean score of MDKT was 7.44 (SD3.08).
A significant positive correlation between MMAS and MDKT scores were found (n
505, rs  0.456, p  0.001). A significant association between knowledge levels and
adherence levels was found (p0.05). The correlation coefficient between HbA1C
and total knowledge score was – 0.39 (p 0.001). Higher diabetes knowledge was a
significant predictor of higher medication adherence (OR  1.381, p  0.001).
CONCLUSIONS: Medication adherence is moderately related with diabetes knowl-
edge. Deficiencies in patients’ knowledge may be the greatest barriers to improving
adherence and improvement of patients’ knowledge could result in better medica-
tion adherence.
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OBJECTIVES: To evaluate the general practitioners’ (GPs) reasons for prescribing
pioglitazone 15 or 30 mg and characterise the patients on these doses. METHODS:
An internet-based survey was conducted among 245 UK GPs who selected reasons
for prescribing pioglitazone 15 or 30 mg/day for their patients. Eligible patients
were 18 years at type 2 diabetes mellitus (T2DM) diagnosis and currently on
pioglitazone (15 or 30 mg) with other oral antihyperglycaemic agents for 3
months. GPs provided clinical data for1 patient on each pioglitazone dose. The 29
potential reasons for prescribing the current pioglitazone dose were classified into
4 categories: sufficient glycaemic control, poor tolerability and/or side effects as-
sociated with pioglitazone, comorbidity/polypharmacy, and patient-related
factors.RESULTS:Of the 1456 patients provided by GPs, 739 were on pioglitazone 15
mg and 717 on 30 mg. Compared with the 30-mg group, patients in the 15-mg group
had a shorter duration of T2DM (median 7.3 vs. 8.3 years) and the same median
HbA1c level (7.2%). Collectively, reasons in the sufficient glycaemic control category
were selected most for both groups; however, they were selected more often for 15
than 30 mg (85 vs. 75%, p0.0001). Specifically, new user was selected for 26% on
15 mg and 11% on 30 mg (p0.0001). No significant differences between groups
were seen within the other categories. Overall, 37% of GPs selected reasons related
to poor tolerability and/or side effects, 42% for comorbidity/polypharmacy, and
30% for patient-related factors. GPs indicated they had no plans to change the
current pioglitazone dose for 58% on 15 mg and 66% on 30 mg. CONCLUSIONS: UK
GPs in this study appear comfortable with their current pioglitazone dose choice for
their patients and a majority of GPs planned to have their patients continue on
their current pioglitazone dose in combination therapy.
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OBJECTIVES: To explore the utility of a novel Subgroup Identification Tool (SIT) in
a healthcare database; specifically to identify which patient subgroup would
achieve better outcome from which treatment option.METHODS: For the purposes
of this study, two cohorts of patients with type II diabetes were extracted from the
UK General Practice Research Database. Study patients were 40 years old, were
newly prescribed with antidiabetics Drug A or Drug B, and had at least 6-month
pre-index and 12-month post-index history. The index date was defined as the date
of first prescription for Drug A or Drug B. The outcome was the average HbA1c from
3 months post-index to the end of 12-month follow-up. Subgroups were con-
structed using the SIT, which employs a novel SIDES (subgroup identification based
on differential effect search) methodology. RESULTS: A total of 4824 patients were
identified initiating Drug A and 1007 patients initiating Drug B. Slightly more pa-
tients achieved HbA1c7% for Drug A (46.4%) compared with Drug B (42.6%), trans-
lating to the number needed to treat (NNT) of 26 in favor of Drug A. The SIT iden-
tified a subgroup (male, 71 years old without a prescription for antihypertensives)
where the Drug A patients responded more favorably than Drug B in terms of
achieving HbA1c 7% (NNT 8 in favor of Drug A); and a subgroup (female, low
density cholesterol 120mg/dl with a prescription for angiotensin-converting en-
zyme inhibitors) where the Drug-B patients responded more favorably (NNT 10 in
favor of Drug B). CONCLUSIONS: This study indicates that the SIT can be useful
when applied to healthcare data to identify subgroups that are more likely to
achieve better outcome from one of the two comparative treatment options. The
results from the SIT could be used for hypothesis generation. Validation using
independent data is warranted.
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OBJECTIVES: To validate the recently updated Charlson Comorbidity Index (CCI)
for the prediction of healthcare utilization and to compare its predictive power in
patients with diabetes or asthma.METHODS:Data were retrieved from the Medical
Expenditure Panel Survey (MEPS) Panel 12 (2007-2008) for this retrospective cohort
study. The original CCI (CCI-1) and updated CCI (CCI-2) scores were calculated for
patients who had diabetes or asthma in 2007. Adjusted R2 from linear regression
models were used for the estimation of log-transformed healthcare expenditures
(COST) in 2008. C statistics from logistic regression models were used to compare
the predictive power of the risk of hospitalizations ( 1 admission), risk of emer-
gency department visits ( 1 visit), and high expenditures ( 90th percentile of
COST) in 2008. RESULTS: 833 diabetic patients and 704 asthmatic patients were
included in the study. The diabetes cohort had a mean age of 59.7 years (SD: 15.3),
and 54% were female; the asthma cohort had a mean age of 37.8 years (SD: 23.6),
and 59% were female. In the linear regressions, the CCI-2 explained more variance
in COST in diabetic patients than in asthmatic patients (adjusted R2  17.4% vs.
14.1%), adjusting for demographics. The CCI-2 was a better predictor of high COST
(c  0.881 vs. 0.816) and the risk of hospitalization (c  0.713 vs. 0.682) but a poorer
predictor of the risk for an emergency department visit (c  0.583 vs. 0.653) in the
diabetes cohort than in the asthma cohort. In both cohorts, the CCI-2 (c  0.583 to
0.881) exhibited consistently better predictive power than the CCI-1 (c  0.576 to
0.839). CONCLUSIONS: The predictive power of CCI varies depending on the out-
comes of interest in patients with diabetes or asthma. The updated CCI showed
improved predictive performance compared to the original CCI.
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OBJECTIVES: To develop a method to adjust the medication possession ratio (MPR)
for type 2 diabetes patients who used a vial or pen form of insulin.METHODS:Using
a retrospective analysis of large US health claims data from 2003 to 2008, diabetes
patients who had at least two insulin prescription fills during the pre-index period
were selected. The index date was the date of the first fill of insulin during the
identification period from 2004 to 2007. One year of pre- and post-index continuous
enrollment was required. Patients were excluded from the study if they switched to
another form of insulin during the post-index period or had a diagnosis of gesta-
tional diabetes during the pre- or post-index period. MPR was calculated as a mea-
sure of drug adherence for patients who used vial insulin (&#x0018;Vial
Cohort&#x0019;), and for those who used pen form insulin (’Pen Cohort’). Since
insulin is a multi-dose treatment and is available in several package sizes, tradi-
tional MPR calculation is not suitable for this study. We adjusted the MPR by mul-
tiplying the traditional MPR by (average days between prescription refills/average
days’ supply) for patients in both cohorts. RESULTS: The unadjusted MPR during
the post-index period for patients who used the pen device is lower than for pa-
tients who used a vial (0.55 vs. 0.60, p0.0082). After controlling for baseline patient
characteristics as well as the differences in package size between the pen and vial
insulin using the new calculation method, the adjusted MPR for patients in the ’Pen
Cohort’ was higher than for patients in the ’Vial cohort’ (0.22 vs. 0.13, p0.001).
CONCLUSIONS: After modifying the traditional MPR by adjusting the package size
of the pen or vial insulin device, the adjusted MPR showed that pen insulin users
had a significant advantage in drug adherence over vial users.
PDB82
DEVELOPMENT OF A HEALTH ECONOMIC MODEL TO COMPARE THE
PREVENTION, TREATMENT AND MANAGEMENT STRATEGIES OF TYPE 2
DIABETES
Nagy B1, Nagyjanosi L2, Nagyistok S2, Józwiak-Hagymásy J2, Dessewffy Z3, Kalo Z4,
Vokó Z1
1Eötvös Loránd University, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary,
3Novartis Hungary, Budapest, Hungary, 4Eötvös Loránd University, Budapest, Hungary
OBJECTIVES: The growing prevalence of diabetes mellitus highlights the conflict
between the burden of disease and sustainability of health care systems, especially
in Central-Eastern European middle income countries. Open access health eco-
nomic models that calculate the effects of health policy programs and public in-
terventions can improve the appropriateness of decisions. Our objective was to
develop a long term economic model for type 2 diabetes and make it available for
public sector decision-makers to support evidence based health policy decisions.
METHODS: The health economic model projects outcomes for selected patient
populations, taking into account baseline patient characteristics, history of com-
plications, changes in physiological parameters over time, diabetes treatment and
management strategies, and screening programs. First section of the model exam-
ines secondary prevention strategies of type 2 diabetes in a decision tree structure.
The second section simulates patients through interconnected Markov sub-models
that replicate important complications of diabetes (ischemic heart disease, reti-
nopathy, hypoglycaemia, nephropathy, neuropathy, foot ulcer, peripherial vascu-
lar disease, stroke and ketoacidosis). Treatment and management strategies are
taken into account when modeling patient pathways. The model includes a wide
range of economic and clinical input data to support adaptability, country- or pro-
vider-specific outcomes and the analysis of different policy and treatment
strategies. RESULTS: In this paper we present the methodological approach, the
model structure, main scientific evidences applied and the choice of policy or treat-
ment strategies that can be examined. CONCLUSIONS: Evidence based health pol-
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icy can be implemented only if decision-makers have the access to analytical tools
to address different policy scenarios. It requires initial investment, which pays off
in better decisions.
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OBJECTIVES: The aim of the current study is to utilize two different methodologies
to estimate the prevalence and burden of type 2 diabetes (T2D) and obesity among
the adult population in France. METHODS: Two separate representative data
sources were used for the adult French population. Data from the French respon-
dents of the EU National Health and Wellness Survey (NHWS) (N15,051) and the
OBEPI survey (N25,286) were used. The NHWS is an internet-based annual survey
and the OBEPI is a mailed survey conducted every three years, validated by the
French authorities. Prevalence information for T2D, comorbid treatments, and BMI
were analyzed using both data sources. The humanistic and economic burden of
T2D was analyzed only from the NHWS data. RESULTS: From NHWS, 44.3% of
respondents from France were male and the average age was 45.1 years (SD15.5).
From OBEPI, 47.8% were male and the average age was 48.2 years (SD17.8). A total
of 30.5% (OBEPI31.9%) and 15.6% (OBEPI14.5%) of the French population were
estimated to be overweight and obese, respectively. A total of 4.4% (from NHWS)
and 4.8% (from OBEPI) of the adult French population reported suffering from T2D.
Among these patients, 15.1% and 80.5% were taking an insulin and oral treatment,
respectively (12.4% by OHAinsulin and 76.0% by OHA only as estimated by OBEPI).
From NHWS, a significant burden was observed among patients with T2D as they
reported significantly lower levels physical quality of life (using the SF-12v2; 42.6
vs. 50.1, p.05) and significantly greater work impairment (26.7% vs. 18.2%, p.05)
and physician visits (8.7 vs. 5.5, p.05). CONCLUSIONS: Both internet and mailed
survey methodologies provided consistent prevalence estimates of diabetes and
obesity among the French population. Further, despite the high prevalence of treat-
ment, significant effects are observed on health outcomes among T2D patients,
highlighting the unmet need.
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OBJECTIVES: According to DATASUS, from 1996 to 2005, there were more than 1
million hospitalizations related to smoking, with total costs sum of half billion
dollars. The aim of this study was to assess the cost-effectiveness of varenicline
compared to other existing strategies for smoking cessation in an adult population
cohort from the public payer’s perspective. METHODS: The Benefits of Smoking
Cessation on Outcomes (BENESCO) simulation model was used for an 18 years of
age and older cohort of 557,881 smokers, within a lifetime time horizon. Smoking
cessation therapies in comparison were: varenicline (0.5–2 mg/day), bupropion (300
mg/day), nicotine replacement therapy (NRT) (5-10 mg/day), and unaided cessa-
tion. Relapse rates were considered as 6.3% for the first 5 years after cessation, 2%
for years 6 to 10 and 1% for subsequent years. Effectiveness measure was Life-Year
gained (LYG). Smoking and smoking-related heath condition’s prevalence, re-
source use and costs data were obtained from DATASUS, INCA (National Cancer
Institute), INCOR (Heart Institute) and DECIT (Science and Technology Department
of Brazil). The model used a 5% discount rate for health outcomes and costs were
expressed in 2010 USD. RESULTS: LYG for varenicline was 7310 compared to 7295
from bupropion, 7294 from nicotine replacement therapy and 7273 for untreated
treatment. Compared to untreated patients, varenicline reduced smoking-related
morbidity by 10,757 events, prevented 8,612 early deaths due to smoking related
events, representing savings for US$139.602.241,20 from heathcare expenses. The
net average cost per additional quitter showed that varenicline was cost-saving
against bupropion (- USD 1.122,00) and nicotine replacement therapy (- US$
46.184,40). CONCLUSIONS: Smoking cessation therapy with varenicline is cost-
saving for Brazil. These results could help to reduce the tobacco related disease
burden while agreeing with cost-containment policies.
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OBJECTIVES: To demonstrate Rx data application in relation to comparative effec-
tiveness of inhaled corticosteroids (ICS) through evaluation of the rate of adher-
ence to drug therapy and consumption of rescue medications in respiratory im-
paired patients. METHODS: Participants: A total of 533,382 patients age 18 or older
who filled a prescription for ICS drugs. Setting: More than 12,153 community phar-
macies nationwide. Data were from computerized pharmacy records. Design: The
persistency analysis included prescription data for ICS dispensed during a 4-month
period. Patient prescription activity was followed for 360 days. Patients were mon-
itored for consumption of short acting beta agonist (SABA) medication in combi-
nation with their index ICS for 360 days from their ICS index fill date. An average
SABA consumption in days for each index ICS drug was calculated. RESULTS: Per-
sistence with ICS is generally poor; about 60% to 78% of patients drop off therapy
within the first 30 days of therapy. Fluticasone/salmeterol (F/S) combination shows
the best persistence and budesonide the worst persistence. Children were more
persistent with mometasone whereas patients 19-60 and 60were more persistent
with F/S. Budesonide and triamcinolone had the worst persistence with all age
groups. The same results were seen in patients with multiple co-morbidities. Per-
sistency with ICS across different co-morbid condition was consistent. On average
67% to 91% of ICS users took a SABA concomitantly. Budesonide (N69,432) pa-
tients on average used fewer days of SABA therapy (higher control), whereas
budesonide/formeterol combination (N25,763) patients used more days of SABA
therapy (lower control). CONCLUSIONS: Rx data can be used to compare effective-
ness of drugs in a class across different population segments. Our analysis showed
that different ICSs have different effectiveness, as indicated by the rate of adher-
ence to therapy and use of rescue medication, in different individuals.
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OBJECTIVES: To model the outcomes associated with alpha-1-antitrypsin defi-
ciency (AATD) related emphysema, an orphan disease, through the use of a Markov
cohort model. METHODS: A simulated cohort of 773 patients (the number pre-
dicted patients in the UK) were transitioned between seven health states: mild,
moderate, severe, very severe, lung transplantation, post lung transplantation and
death, according to transition probabilities calculated from pooled randomised
controlled trials. Computed tomography (CT) is accepted to be a more sensitive and
correct measure of progression of disease in AATD-related emphysema, whereas
FEV1 is a more recognised measure of lung function for clinical management of
pulmonary disorders. Thus to model disease progression, CT decline from the
randomised trials was converted to FEV1 decline through two different mapping
algorithms, and transition probabilities calculated accordingly. Health-Related
Quality of Life decreases as disease progresses, with utility values taken from the
literature. At the stage where FEV1 % predicted fell below an eligible threshold,
patients underwent lung transplantation. A predefined limitation on the number of
lungs available reflected the competition for lung transplantation in the healthcare
system. The model outputs include Life Years, QALYs, Lung transplantations, and
disease specific mortality. All values were discounted at 3.5%. RESULTS: AAT re-
placement therapy resulted in an increase of 0.32 life years (6.93 vs. 6.61), with an
estimated gain of 0.28 QALYs per patient (4.64 vs. 4.27) over best supportive care.
For a cohort of 773 patients over a lifetime horizon, 19 AAT deficiency deaths and 6
lung transplantations were avoided when patients were treated with AAT com-
pared to best standard care. CONCLUSIONS: Treatment with AAT slows decline in
lung function and delays death associated with AATD. By slowing lung function
decline, patients experience improved health related quality of life, while fewer
lung transplantations are required, increasing the number of donor organs avail-
able for use in other diseases.
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OBJECTIVES: To assess the effectiveness on treatment adherence of a multifacto-
rial intervention in patients with COPD. METHODS: Design: Randomized Control
Trial (ISRCTN 15106246) Patients: 146 subjects randomly allocated (random blocks
of 4 patients) in two groups (intervention group: IG, control group: CG). Intervention
components: 1) Motivational aspects related with adherence: beliefs-behaviour
about COPD (group and individual interviews); 2) Cognitive aspects: information
about illness; and 3) Skills: inhaling techniques training. Follow-up: 1 year, 5 visits/
group: 1) V0 random allocation, all variables were measured; 2) V0C adherence was
measured; 3) V1-V2 (3-6 moths after start/intervention) adherence and variable
changes were measured; and 4) V3 (one year after start/intervention) all variables
were measured. Primary Outcome: adherence (doses recount); Secondary Out-
comes: functional status (spirometry), quality of life (Saint George Respiratory
Questionnaire-SGRQ); Independent variables: age, sex, educational level, comor-
bidity, COPD severity stage (SEPAR guidelines), prescribed medication. RESULTS:
Predominace of males (91.8%), mean age 69.01 years (CI95%, 67.58-70.44); low cul-
tural level (78.1%), 32.2% current smokers (29.36 cigarettes/day [CI 95%, 26.03-32.7])
overweight (Body Mass Index 30.78 kg/m2 [CI 95%, 28.78-32.78]), 81.2% mild-mod-
erate severity stage, predominance of obstructive respiratory pattern; FEV1
(mean)68.76% (CI 95%, 65.23-72.29), 0.87 exacerbations/year [CI95%, 0.68-1.06].
Pharmacological treatment: inhaled-anticholinergic (77.4%); inhaled-beta2-ad-
renérgic (80.1%); inhaled-corticosteroids (70.5%); xantins (8.2%); oxygen therapy
(4.8%); oral-corticosteroids (0.7%); mucolytics (11.6%). All these measurements
were similar in both groups. Adherence was 41% (41.2CG/40.8IG). 93 patients
(63.7%) completed follow-up. Adherence in follow-up V161.8% (58.9CG/65.2IG),
V266.3% (63.2CG/71.1IG), V356.8% (43.1CG/72.7IG). Significative differences be-
tween study groups (p0.004). NNT for intervention:6,8 .Multivariate analysis (Ad-
herence): (specificity  87.5%, sensibility  60.4%): intervention [OR6.066 (IC95%,
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